These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37403986)

  • 41. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions.
    Hazafa A; Mumtaz M; Farooq MF; Bilal S; Chaudhry SN; Firdous M; Naeem H; Ullah MO; Yameen M; Mukhtiar MS; Zafar F
    Life Sci; 2020 Dec; 263():118525. PubMed ID: 33031826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different Methods of Delivering CRISPR/Cas9 Into Cells.
    Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
    Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
    Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
    Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficient Mitochondrial Genome Editing by CRISPR/Cas9.
    Jo A; Ham S; Lee GH; Lee YI; Kim S; Lee YS; Shin JH; Lee Y
    Biomed Res Int; 2015; 2015():305716. PubMed ID: 26448933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (
    Shen Y; Cohen JL; Nicoloro SM; Kelly M; Yenilmez B; Henriques F; Tsagkaraki E; Edwards YJK; Hu X; Friedline RH; Kim JK; Czech MP
    J Biol Chem; 2018 Nov; 293(44):17291-17305. PubMed ID: 30190322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Research progress of CRISPR-Cas9 system for gene therapy].
    Zhan C; Xia X
    Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
    Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
    Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CRISPR/Cas9-mediated genome editing in sea urchins.
    Lin CY; Oulhen N; Wessel G; Su YH
    Methods Cell Biol; 2019; 151():305-321. PubMed ID: 30948015
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRISPR/Cas gene therapy.
    Zhang B
    J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment.
    Wei Y; Zhao Z; Ma X
    Front Immunol; 2022; 13():1037124. PubMed ID: 36479105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Kayesh MEH; Hashem MA; Kohara M; Tsukiyama-Kohara K
    Front Microbiol; 2022; 13():953218. PubMed ID: 35847068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma.
    Liu WL; Green N; Seymour LW; Stevenson M
    Cancer Gene Ther; 2009 Oct; 16(10):764-75. PubMed ID: 19363466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
    Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
    ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets.
    Zhu H; Zhang L; Tong S; Lee CM; Deshmukh H; Bao G
    Nat Biomed Eng; 2019 Feb; 3(2):126-136. PubMed ID: 30944431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
    Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
    Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Applications of the CRISPR-Cas9 system in kidney research.
    Higashijima Y; Hirano S; Nangaku M; Nureki O
    Kidney Int; 2017 Aug; 92(2):324-335. PubMed ID: 28433382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent Advances in CRISPR/Cas9 Delivery Strategies.
    Yip BH
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.